TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Non-invasive hemoglobin reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of neonatal sepsis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Health risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of risk behaviors counseled on during primary care appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adolescent Satisfaction with Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incremental Cost Utility ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tissue distribution of 99mTc-MIP-1404
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive Tartrate-resistant acid phosphatase (TRAP) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Scale for Suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Corticospinal motor excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complications/side-effects/tolerability/toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in systolic blood pressure (SBP) from sitting to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in B-Glucuronidase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response to Induction Chemotherapy (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum allopregnanolone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regimen Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Escalation in respiratory related care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: disease-free time to progression
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intensities of multiple serum metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensities of multiple urinary metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate (more than stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy in T stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients using atypical antipsychotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily dosage of atypical antipsychotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mode of administration of atypical antipsychotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mental Health Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Agreement Between Eye-tracking Biomarker and Expert Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiac Events (MACE) days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: surgical approach evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of Bleeding Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hair regrowth by dermoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair regrowth by optical coherence tomography (OCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Impact on Usual Activities Scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Water intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of breakthrough IFD
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Half-Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen consumption (VO2)/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Oxygen Pulse (O2-Pulse)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative patency of inner covered stent and Two-in-one stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain Free
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sexual Compulsivity Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Completely Cured of Reflux Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of immunoglobulin (IGA, IgM, IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th1 / Th2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First Event of Cardiovascular Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Re-hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Extended Initial Hospital Stay Due to Diagnosis of Heart Failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: change in Walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in stride length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neck function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in subepithelial infiltrates number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in Schirmer type 1 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The International Restless Legs Scale (IRLS) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Newborn Survival at Birth
Endpoint domain: Mortality/survival
Primary endpoint: Helkimo Clinical Dysfunction Score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum incisal opening improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection Success of Vector Mosquitoes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Severity of leishmaniasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell ARA and DHA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activity Based Total Visual Analog Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Grade 2 or Higher Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antifungal treatment plasmatic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution for plasmatic antifungal treatment concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for plasmatic antifungal treatment concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Were Treatment Failures
Endpoint domain: Adverse events/effects
Primary endpoint: MPL functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of incontinence episode frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of most prevalent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Leading to Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Intentions to quit smoking in the next 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heel Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CYP2C19 genetic polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of ALDH3A1 genetic polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SRSF2 gene mutation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abnormal scores on Strength and Difficulties Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant alcohol and drug problems
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of biomarkers (APF, HB-EGF, MCP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who reported at least one ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Invasive Fungal Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Short-form 12 questionnaire (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severe local toxicity at injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Severe systemic symptoms related to the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with therapeutic failure on thiopurines
Endpoint domain: Adverse events/effects
Primary endpoint: Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic yield of mucosal biopsy samples with neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CDVA in first implanted eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Visual outcomes
Primary endpoint: DCIVA in first implanted eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Visual outcomes
Primary endpoint: DCNVA in first implanted eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Visual outcomes
Primary endpoint: range of motion in degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: force in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain with the digital pain scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: functional score with the Quick DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ratio of patients with superior outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to the first asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean log10 reductions from baseline populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of New Diabetes Per Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-stroke fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 3-month locoregional control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with no significant toxicities responsible for irradiation breaks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adequate biopsy samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving LDL Level ≤ 100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax for Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax for Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Target Area Hair Count (TAHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject Self Assessment (Hair Growth Assessment [HGA])
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Subjects With Complete Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Experienced Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Low Density Lipoprotein Cholesterol (LDL-C) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pure tone audiometry (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lesion evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical - GABA measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical - GHB measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of GABA related signals on the MRI spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Complete and Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormalities in vital signs, ECG, and clinically significant laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-diagnosed pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in academic grades
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in academic attendance rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in social functioning of students receiving services
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Disease inactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of Helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of peptic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of all serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-PhtD antibody concentration
Endpoint domain: Physiological/clinical
Primary endpoint: Psychiatric Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of UB-612 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of ADVAX
Endpoint domain: Adverse events/effects
Primary endpoint: Presence/absence of S100B > 0.2 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 week change in total score of Major Depression Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3 week change in total score of Eating Disorder Inventory 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3 week change in video images based measure of Physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Stapler Performance Issues
Endpoint domain: Adverse events/effects
Primary endpoint: failure percentage of the diagnostic strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of HCWs hospitalized due to COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical improvement of IC stented patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional improvement of IC stented patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow velocity across Stenotic Large IC Vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in severity based on VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete resolution based on VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete cessation of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal increase in copeptin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of confirmed COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained response (HBeAg seroconversion and HBV DNA <2000 IU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical asthma score (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of labour induction after 24 hours from PROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Counts of Human Papillomavirus (HPV) Vaccine Initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximal Tolerable Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Reaction Time (RTI) Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nightime voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-week Progression Free Rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of significant toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Spleen size (or volume) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference Over 3 Days (SPID72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Satisfaction Subscales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: energy content of snacks purchased
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with treatment-related adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of kidneys procured and discarded
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Induction of sustained ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum potential duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activation recovery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endurance time during an endurance shuttle walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incretins concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inhibition of the P2Y12 Receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes